Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™

MIAMI, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company deve...

Related Keywords

Miami ,Florida ,United States ,Japan ,Mike Moyer ,Trademark Office ,Longeveron Or Company ,Nasdaq ,Exchange Commission On ,Japan Pharmaceuticals ,Longeveron Inc ,Devices Agency ,European Union ,Exchange Commission ,United States Patent ,Medicinal Signaling Cells ,Aging Related Frailty ,Medical Devices Agency ,Regenerative Medicine ,Chief Scientific Officer ,Hypoplastic Left Heart Syndrome ,Patent Application ,Mesenchymal Stem Cells ,Vaccine Adjuvants ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,